PE20091556A1 - Derivado heterociclico fusionado y su uso - Google Patents

Derivado heterociclico fusionado y su uso

Info

Publication number
PE20091556A1
PE20091556A1 PE2009000279A PE2009000279A PE20091556A1 PE 20091556 A1 PE20091556 A1 PE 20091556A1 PE 2009000279 A PE2009000279 A PE 2009000279A PE 2009000279 A PE2009000279 A PE 2009000279A PE 20091556 A1 PE20091556 A1 PE 20091556A1
Authority
PE
Peru
Prior art keywords
oxo
piperidin
phenylethyl
carboxamide
dihydro
Prior art date
Application number
PE2009000279A
Other languages
English (en)
Inventor
Nobuhiro Fujii
Shigeru Kondo
Yuya Oguro
Satoshi Sasaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20091556A1 publication Critical patent/PE20091556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I) DONDE A ES ANILLO DE 5 A 7 MIEMBROS OPCIONALMENTE SUSTITUIDO; X ES O, S O NR1; R1 ES H, HIDROCARBURO DE FORMA OPCIONAL; R2 ES CARBAMOILO OPCIONALMENTE SUSTITUIDO; R3 ES OH OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS SELECCIONADOS: N-[1-(2-HIDROXIETIL)PIPERIDIN-4-IL]-3-METOXI-1-METIL-4-OXO-5-(2-OXO-2-FENILETIL)-4,5-DIHIDRO-1H-PIRROLO[3,2-c]QUINOLIN-2-CARBOXAMIDA; N-[1-(2-HIDROXIACETIL)PIPERIDIN-4-IL]-3-METOXI-1-METIL-4-OXO-5-(2-OXO-2-FENILETIL)-4,5-DIHIDRO-1H-PIRROLO[3,2-c]QUINOLIN-2-CARBOXAMIDA; 3-ETOXI-6-ETIL-N-[1-(HIDROXIACETIL)PIPERIDIN-4-IL]-1-METIL-4-OXO-5-(2-OXO-2-FENILETIL)-4,5-DIHIDRO-1H-PIRROLO[3,2-c]PIRIDIN-2-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEINA Smo, UTILES PARA EL TRATAMIENTO DEL CANCER
PE2009000279A 2008-02-26 2009-02-25 Derivado heterociclico fusionado y su uso PE20091556A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008045134 2008-02-26
JP2008256755 2008-10-01

Publications (1)

Publication Number Publication Date
PE20091556A1 true PE20091556A1 (es) 2009-11-03

Family

ID=40905094

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000279A PE20091556A1 (es) 2008-02-26 2009-02-25 Derivado heterociclico fusionado y su uso

Country Status (28)

Country Link
US (2) US8399449B2 (es)
EP (1) EP2247588B1 (es)
JP (2) JP4719317B2 (es)
KR (1) KR101569949B1 (es)
CN (1) CN102015705B (es)
AR (1) AR070479A1 (es)
AU (1) AU2009217982B2 (es)
BR (1) BRPI0908417B1 (es)
CA (1) CA2716773C (es)
CL (1) CL2009000429A1 (es)
CO (1) CO6321277A2 (es)
CR (1) CR11661A (es)
DO (1) DOP2010000260A (es)
EA (1) EA020144B1 (es)
EC (1) ECSP10010496A (es)
ES (1) ES2586252T3 (es)
GE (1) GEP20125664B (es)
HK (1) HK1150274A1 (es)
IL (1) IL207735A (es)
JO (1) JO3259B1 (es)
MA (1) MA32164B1 (es)
MX (1) MX2010009372A (es)
MY (1) MY150379A (es)
NZ (1) NZ587719A (es)
PE (1) PE20091556A1 (es)
TW (1) TWI480282B (es)
WO (1) WO2009107850A2 (es)
ZA (1) ZA201006063B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716773C (en) 2008-02-26 2016-04-26 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
NO2459176T3 (es) 2009-07-31 2018-02-24
JPWO2011013752A1 (ja) * 2009-07-31 2013-01-10 塩野義製薬株式会社 縮合へテロ環誘導体を含有する医薬組成物
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
JP5599802B2 (ja) * 2009-08-26 2014-10-01 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011024869A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011024873A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
CA2873097A1 (en) 2012-05-11 2013-11-14 Todd M. Hansen Pyridazine and pyridine derivatives as nampt inhibitors
US9782418B2 (en) * 2013-12-03 2017-10-10 Celestra Life Science Llc Rationale-based design of a targeted therapy for cancer
JP6353031B2 (ja) 2014-03-19 2018-07-04 株式会社東芝 電池用電極材料、非水電解質電池、電池パック及び車
EP3127907A4 (en) * 2014-03-31 2018-04-04 Boston Biomedical, Inc. New tricyclic quinone derivative
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
US9962378B2 (en) * 2015-09-17 2018-05-08 Macau University Of Science And Technology ROS1 inhibitor and its use
HUE057240T2 (hu) 2016-02-01 2022-04-28 Takeda Pharmaceuticals Co Kokristály
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP7091201B2 (ja) 2018-09-14 2022-06-27 株式会社東芝 活物質、電極、二次電池、電池パック、及び車両
RU2711968C1 (ru) * 2018-11-22 2020-01-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский национальный исследовательский политехнический университет" Анальгезирующее средство
CN110172068A (zh) * 2019-06-05 2019-08-27 河南龙湖生物技术有限公司 具有抗肿瘤活性的苯并噻唑类化合物及其制备方法和应用
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
CN113292477B (zh) * 2021-06-01 2023-06-02 四川大学 一种铱催化的碳氢活化反应合成异吲哚-1-酮类化合物的方法
CN113429422B (zh) * 2021-07-26 2022-05-10 中国人民解放军军事科学院军事医学研究院 一种噻吩并喹诺酮类化合物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3012684B2 (ja) 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
WO1993013664A2 (en) 1992-01-11 1993-07-22 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
FR2695126B1 (fr) * 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
JP3223289B2 (ja) 1992-10-22 2001-10-29 東洋アルミニウム株式会社 肉類調理器具および肉類調理方法
SK18542000A3 (sk) 1998-06-04 2001-12-03 Abbott Laboratories Protizápalové zlúčeniny inhibujúce bunkovú adhéziu
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
JP2006151810A (ja) 2002-12-26 2006-06-15 Daiichi Asubio Pharma Co Ltd ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
US20050043346A1 (en) 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
US20070060595A1 (en) 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
US20080249154A1 (en) * 2003-12-26 2008-10-09 Ono Pharmaceutical Co., Ltd. Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
BRPI0509745A (pt) 2004-04-08 2007-09-25 Topotarget As compostos de difenil ox-indol-2-ona e seu uso no tratamento de cáncer
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2008002165A (es) 2005-08-16 2008-04-29 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
AR056560A1 (es) * 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
WO2007085188A1 (en) * 2006-01-27 2007-08-02 Shanghai Hengrui Pharmaceutical Co. Ltd. Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
JP2009536156A (ja) * 2006-04-14 2009-10-08 ノバルティス アクチエンゲゼルシャフト ヘッジホッグ経路関連障害の処置におけるビアリールカルボキサミドの使用
EA018441B1 (ru) * 2007-03-14 2013-08-30 ЭКСЕЛИКСИС ПАТЕНТ КОМПАНИ ЭлЭлСи Ингибиторы пути хеджхога
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
CA2716773C (en) 2008-02-26 2016-04-26 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof

Also Published As

Publication number Publication date
CL2009000429A1 (es) 2009-09-25
CN102015705A (zh) 2011-04-13
AR070479A1 (es) 2010-04-07
BRPI0908417B1 (pt) 2022-01-11
ECSP10010496A (es) 2010-10-30
US20090227561A1 (en) 2009-09-10
US20110003788A1 (en) 2011-01-06
CA2716773C (en) 2016-04-26
AU2009217982B2 (en) 2013-04-11
TWI480282B (zh) 2015-04-11
EP2247588B1 (en) 2016-04-13
JP4719317B2 (ja) 2011-07-06
IL207735A0 (en) 2010-12-30
TW200940548A (en) 2009-10-01
KR101569949B1 (ko) 2015-11-18
BRPI0908417A2 (pt) 2020-08-18
AU2009217982A2 (en) 2010-10-07
US8217176B2 (en) 2012-07-10
WO2009107850A3 (en) 2010-01-28
JO3259B1 (ar) 2018-09-16
AU2009217982A1 (en) 2009-09-03
JP5490030B2 (ja) 2014-05-14
EP2247588A2 (en) 2010-11-10
GEP20125664B (en) 2012-10-10
JP2011513199A (ja) 2011-04-28
MX2010009372A (es) 2010-09-22
US8399449B2 (en) 2013-03-19
HK1150274A1 (zh) 2011-11-18
ES2586252T3 (es) 2016-10-13
NZ587719A (en) 2012-04-27
KR20100137482A (ko) 2010-12-30
IL207735A (en) 2014-12-31
EA201070994A1 (ru) 2011-04-29
CA2716773A1 (en) 2009-09-03
ZA201006063B (en) 2011-10-26
DOP2010000260A (es) 2010-10-15
CR11661A (es) 2010-10-11
MY150379A (en) 2013-12-31
WO2009107850A2 (en) 2009-09-03
EA020144B1 (ru) 2014-09-30
CN102015705B (zh) 2013-11-13
CO6321277A2 (es) 2011-09-20
MA32164B1 (fr) 2011-03-01
JP2011098978A (ja) 2011-05-19

Similar Documents

Publication Publication Date Title
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
AR074876A1 (es) Derivados de indol-pirimidina para tratar cancer
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
ECSP078003A (es) Inhibidores de aspartil proteasas
EA200970156A1 (ru) Пиридизиноновые производные
EA201070278A1 (ru) Ингибиторы гамма-секретазы
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
UY32490A (es) Inhibidores de beta-secretasa
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
EA201100037A1 (ru) Органические соединения
EA200970207A1 (ru) Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
GT201100181A (es) "inhibidores de proteina cinasa"
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
HN2008000949A (es) Derivados de pirimidinil- aril- urea que son inhibidores de fgf
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение

Legal Events

Date Code Title Description
FG Grant, registration